Biological markers of amyloid β-related mechanisms in Alzheimer's disease
Harald Hampel,Yong Shen,Dominic M. Walsh,Paul S. Aisen,Les Shaw,Henrik Zetterberg,John Q. Trojanowski,Kaj Blennow +7 more
Reads0
Chats0
TLDR
This article reviews recent research advances on core candidate CSF and plasma Abeta-related biomarkers, and gives a conceptual review on how to implement biomarkers in clinical trials in AD.Citations
More filters
Journal ArticleDOI
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois,Harald Hampel,Harald Hampel,Howard Feldman,Philip Scheltens,Paul S. Aisen,Sandrine Andrieu,Hovagim Bakardjian,Habib Benali,Lars Bertram,Lars Bertram,Kaj Blennow,Karl Broich,Enrica Cavedo,Sebastian J. Crutch,Jean-François Dartigues,Charles Duyckaerts,Stéphane Epelbaum,Giovanni B. Frisoni,Serge Gauthier,Remy Genthon,Alida A. Gouw,Alida A. Gouw,Marie-Odile Habert,David M. Holtzman,Miia Kivipelto,Miia Kivipelto,Simone Lista,José Luis Molinuevo,Sid E. O'Bryant,Gil D. Rabinovici,Christopher C. Rowe,Stephen Salloway,Lon S. Schneider,Reisa A. Sperling,Reisa A. Sperling,Marc Teichmann,Maria C. Carrillo,Jeffrey L. Cummings,Cliff R. Jack +39 more
TL;DR: An updated review of the literature and evidence on the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage of Alzheimer's disease are provided.
Journal ArticleDOI
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.
Michael W. Weiner,Michael W. Weiner,Dallas P. Veitch,Paul S. Aisen,Laurel A. Beckett,Nigel J. Cairns,Robert C. Green,Danielle J Harvey,Clifford R. Jack,William J. Jagust,Enchi Liu,John C. Morris,Ronald C. Petersen,Andrew J. Saykin,Mark E. Schmidt,Leslie M. Shaw,Judith Siuciak,Holly Soares,Arthur W. Toga,John Q. Trojanowski +19 more
TL;DR: The major accomplishments of ADNI have been the development of standardized methods for clinical tests, magnetic resonance imaging, positron emission tomography (PET), and cerebrospinal fluid (CSF) biomarkers in a multicenter setting, and the improvement of clinical trial efficiency.
Journal ArticleDOI
Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification.
TL;DR: In summary, both SPARE-AD and CSF biomarkers showed high baseline sensitivity, however, many MCI-NC had abnormal baseline Spatial Pattern of Abnormalities for Recognition of Early AD and CSFs, and longer follow-up will elucidate the specificity of baseline measurements.
Journal ArticleDOI
The Alzheimer's Disease Neuroimaging Initiative: Progress report and future plans
Michael W. Weiner,Michael W. Weiner,Paul S. Aisen,Clifford R. Jack,William J. Jagust,John Q. Trojanowski,Leslie M. Shaw,Andrew J. Saykin,John C. Morris,Nigel J. Cairns,Laurel A. Beckett,Arthur W. Toga,Robert C. Green,Sarah Walter,Holly Soares,Peter J. Snyder,Eric Siemers,William Z. Potter,Patricia E. Cole,Mark E. Schmidt +19 more
TL;DR: Structural MRI shows high rates of brain atrophy, and has high statistical power for determining treatment effects, and ADNI provides significant new information concerning the progression of AD.
Journal ArticleDOI
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.
TL;DR: Evidence is presented that links Aβ oligomers to pathogenesis in animal models and humans, with reference to seminal discoveries from cell biology and new ideas concerning pathogenic mechanisms, including relationships to diabetes and Fragile X.
References
More filters
Journal ArticleDOI
Neuropathological stageing of Alzheimer-related changes.
Heiko Braak,Eva Braak +1 more
TL;DR: The investigation showed that recognition of the six stages required qualitative evaluation of only a few key preparations, permitting the differentiation of six stages.
Journal ArticleDOI
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics
John Hardy,Dennis J. Selkoe +1 more
TL;DR: It has been more than 10 years since it was first proposed that the neurodegeneration in Alzheimer's disease (AD) may be caused by deposition of amyloid β-peptide in plaques in brain tissue and the rest of the disease process is proposed to result from an imbalance between Aβ production and Aβ clearance.
Journal ArticleDOI
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Bruno Dubois,Howard Feldman,Claudia Jacova,Steven T. DeKosky,Pascale Barberger-Gateau,Jeffrey L. Cummings,André Delacourte,Douglas Galasko,Serge Gauthier,Gregory A. Jicha,Kenichi Meguro,John T. O'Brien,Florence Pasquier,Philippe Robert,Martin N. Rossor,Steven Salloway,Yaakov Stern,Pieter Jelle Visser,Philip Scheltens +18 more
TL;DR: The NINCDS-ADRDA and DSM-IV-TR criteria for Alzheimer's disease (AD) are the prevailing diagnostic standards in research; however, they have now fallen behind the unprecedented growth of scientific knowledge as discussed by the authors.
Journal ArticleDOI
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.
Robert Vassar,Brian D. Bennett,Safura Babu-Khan,Steve Kahn,Elizabeth A. Mendiaz,Paul Denis,David B. Teplow,Sandra Ross,Patricia Amarante,Richard Loeloff,Yi Luo,Seth Fisher,Janis Fuller,Steven P. Edenson,Jackson Lile,Mark A. Jarosinski,Anja Leona Biere,Eileen Curran,Teresa L. Burgess,Jean Claude Louis,Frank H. Collins,James J. S. Treanor,Gary Rogers,Martin Citron +23 more
TL;DR: Overexpression of a transmembrane aspartic protease, termed BACE (for beta-site APP-cleaving enzyme) increased the amount of beta-secretase cleavage products, and these were cleaved exactly and only at known beta- secretase positions.
Journal ArticleDOI
The Alzheimer's disease neuroimaging initiative
Susanne G. Mueller,Michael W. Weiner,Michael W. Weiner,Leon J. Thal,Ronald C. Petersen,Clifford R. Jack,William J. Jagust,John Q. Trojanowski,Arthur W. Toga,Laurel A. Beckett +9 more
TL;DR: The Alzheimer's Disease Neuroimaging Initiative will help identify clinical, neuroimaging, and biomarker outcome measures that provide the highest power for measurement of longitudinal changes and for prediction of transitions.